Fiche société
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Traitements, essais et publications liés.
Traitements12programmes
Essais9liés
Publications7liées
SourceDBlocale
Traitements
12| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Atogepant 60 mgThis goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits. | Migraine | À vérifier | À vérifier | Spain | À vérifier |
| Monoclonal antibody anti-CGRPBeing able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine. | Migraine | À vérifier | À vérifier | Spain | À vérifier |
| PREDI-CRISIS — Migraine Attack Pain Phase Prediction StudyThe study of the ability to predict pain in a migraine attack, through premonitory symptoms and through an ambulatory monitoring device through real-time recording of hemodynamic variables, is one of the strategic lines of research of the unit. of Headaches at the Hospital de La Princesa since 2013 together with the Complutense and Polytechnic University of Madrid. Their results have been reflected in various publications (Pagán J, et al. Sensors 2015; Gago-Veiga AB, et al. J Pain Res 2018) and have promoted the creation of several invention patents. | Migraine | À vérifier | Traitement symptomatique | Spain | À vérifier |
| PREDI-CRISIS — Migraine Attack Pain Phase Prediction StudyThe study of the ability to predict pain in a migraine attack, through premonitory symptoms and through an ambulatory monitoring device through real-time recording of hemodynamic variables, is one of the strategic lines of research of the unit. of Headaches at the Hospital de La Princesa since 2013 together with the Complutense and Polytechnic University of Madrid. Their results have been reflected in various publications (Pagán J, et al. Sensors 2015; Gago-Veiga AB, et al. J Pain Res 2018) and have promoted the creation of several invention patents. | Migraine | À vérifier | Traitement symptomatique | Spain | À vérifier |
| Atogepant 60 mgThis goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits. | Migraine | Phase 4 | À vérifier | United States | À vérifier |
| Atogepant 60 mgThis goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits. | Migraine | À vérifier | À vérifier | Spain | À vérifier |
| Atogepant 60 mgThis goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits. | Migraine | Phase 3 | À vérifier | United States, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, South Korea, Spain, Taiwan, United Kingdom | À vérifier |
| Atogepant 60 mgThis goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits. | Migraine | À vérifier | À vérifier | Italy | À vérifier |
| Monoclonal antibody anti-CGRPBeing able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine. | Migraine | À vérifier | À vérifier | Spain | À vérifier |
| Atogepant 60 mgThis goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits. | Migraine | Phase 3 | À vérifier | Japan | À vérifier |
| Atogepant 60 mgThis goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits. | Migraine | À vérifier | À vérifier | Italy | À vérifier |
| Atogepant 60 mgThis goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others. Research participants will: * Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits. | Migraine | Phase 3 | À vérifier | United States, Australia, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Russia, Spain, Sweden, United Kingdom | À vérifier |
Essais cliniques
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Atogepant 60 mg | Migraine | Phase 3 | NCT04740827 | ELEVATE — Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. | COMPLETED |
| Atogepant 60 mg | Migraine | À vérifier | NCT06882122 | ATOM — Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine | RECRUITING |
| Atogepant 60 mg | Migraine | Phase 3 | NCT04437433 | JPN ATO OLE — A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine | COMPLETED |
| Monoclonal antibody anti-CGRP | Migraine | À vérifier | NCT06459648 | PREDI-CGRP — Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies | RECRUITING |
| Atogepant 60 mg | Migraine | À vérifier | NCT06414044 | STAR — Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients | ACTIVE_NOT_RECRUITING |
| Atogepant 60 mg | Migraine | Phase 3 | NCT04686136 | A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine | COMPLETED |
| Atogepant 60 mg | Migraine | À vérifier | NCT07699549 | GEMA PROJECT — Long-term Atogepant in Real-world Practice | COMPLETED |
| Atogepant 60 mg | Migraine | Phase 4 | NCT06972056 | Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study | RECRUITING |
| PREDI-CRISIS — Migraine Attack Pain Phase Prediction Study | Migraine | À vérifier | NCT06459635 | PREDI-CRISIS — Migraine Attack Pain Phase Prediction Study | RECRUITING |
Publications
7| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Atogepant 60 mg | Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial. | The Lancet. Neurology | ||
| PREDI-CRISIS — Migraine Attack Pain Phase Prediction Study | Waning light, waxing pain: The lunar cycle's association with migraine headache occurrence. | Headache | ||
| PREDI-CRISIS — Migraine Attack Pain Phase Prediction Study | Forecasting migraine with time-series machine learning from mobile health data. | The journal of headache and pain | ||
| Atogepant 60 mg | Atogepant Reduces Psychological Dependence on Acute Treatments Evaluated With the Leeds Dependence Questionnaire: A Prospective Study. | Brain and behavior | ||
| Atogepant 60 mg | Real-life effectiveness, tolerability, and safety of atogepant: a prospective, observational, multicentre study by the Headache Study Group in Castile-La Mancha. | Neurologia | ||
| PREDI-CRISIS — Migraine Attack Pain Phase Prediction Study | Frontal Delta Decreasing and Occipital Ictal Alpha Increasing Associated With Migraine in Preictal and Ictal Phases. | IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society | ||
| PREDI-CRISIS — Migraine Attack Pain Phase Prediction Study | The role of prodromal symptoms in predicting headache onset: A longitudinal electronic momentary assessment study. | Headache |